Free Trial
NASDAQ:OCX

OncoCyte (OCX) Stock Price, News & Analysis

OncoCyte logo
$3.18 +0.45 (+16.30%)
Closing price 06/17/2025
Extended Trading
$3.18 0.00 (0.00%)
As of 06/17/2025 07:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About OncoCyte Stock (NASDAQ:OCX)

Key Stats

Today's Range
$2.71
$3.21
50-Day Range
$2.60
$3.44
52-Week Range
$1.92
$4.75
Volume
100,514 shs
Average Volume
58,089 shs
Market Capitalization
$90.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.06
Consensus Rating
Moderate Buy

Company Overview

OncoCyte Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
40th Percentile Overall Score

OCX MarketRank™: 

OncoCyte scored higher than 40% of companies evaluated by MarketBeat, and ranked 654th out of 913 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    OncoCyte has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    OncoCyte has only been the subject of 3 research reports in the past 90 days.

  • Read more about OncoCyte's stock forecast and price target.
  • Earnings Growth

    Earnings for OncoCyte are expected to grow in the coming year, from ($2.57) to ($1.40) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of OncoCyte is -0.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of OncoCyte is -0.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about OncoCyte's valuation and earnings.
  • Percentage of Shares Shorted

    1.32% of the float of OncoCyte has been sold short.
  • Short Interest Ratio / Days to Cover

    OncoCyte has a short interest ratio ("days to cover") of 4.7.
  • Change versus previous month

    Short interest in OncoCyte has recently decreased by 7.88%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    OncoCyte does not currently pay a dividend.

  • Dividend Growth

    OncoCyte does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.32% of the float of OncoCyte has been sold short.
  • Short Interest Ratio / Days to Cover

    OncoCyte has a short interest ratio ("days to cover") of 4.7.
  • Change versus previous month

    Short interest in OncoCyte has recently decreased by 7.88%, indicating that investor sentiment is improving significantly.
  • Search Interest

    Only 1 people have searched for OCX on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, OncoCyte insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 2.05% of the stock of OncoCyte is held by insiders.

  • Percentage Held by Institutions

    55.35% of the stock of OncoCyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about OncoCyte's insider trading history.
Receive OCX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OncoCyte and its competitors with MarketBeat's FREE daily newsletter.

OCX Stock News Headlines

Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.
See More Headlines

OCX Stock Analysis - Frequently Asked Questions

OncoCyte's stock was trading at $2.38 at the start of the year. Since then, OCX stock has increased by 33.4% and is now trading at $3.1750.

OncoCyte Corporation (NASDAQ:OCX) announced its earnings results on Monday, May, 12th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.24) by $0.02. The company had revenue of $2.14 million for the quarter, compared to the consensus estimate of $0.13 million. OncoCyte had a negative trailing twelve-month return on equity of 215.59% and a negative net margin of 1,516.06%.
Read the conference call transcript
.

OncoCyte shares reverse split before market open on Tuesday, July 25th 2023.The 1-20 reverse split was announced on Tuesday, July 25th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, July 25th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Shares of OCX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that OncoCyte investors own include Alibaba Group (BABA), Meta Platforms (META), Fulcrum Therapeutics (FULC), VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), CymaBay Therapeutics (CBAY) and Ford Motor (F).

Company Calendar

Last Earnings
5/12/2025
Today
7/08/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Medical Services
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:OCX
Employees
120
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.06
High Stock Price Target
$8.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+90.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$60.66 million
Net Margins
-1,516.06%
Pretax Margin
-1,514.57%

Debt

Sales & Book Value

Annual Sales
$3.84 million
Price / Cash Flow
N/A
Book Value
($0.70) per share
Price / Book
-4.54

Miscellaneous

Free Float
28,013,000
Market Cap
$90.80 million
Optionable
No Data
Beta
0.97
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

This page (NASDAQ:OCX) was last updated on 7/8/2025 by MarketBeat.com Staff
From Our Partners